241 related articles for article (PubMed ID: 20587517)
1. STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer.
Wang L; Jin Y; Arnoldussen YJ; Jonson I; Qu S; Maelandsmo GM; Kristian A; Risberg B; Waehre H; Danielsen HE; Saatcioglu F
Cancer Res; 2010 Jul; 70(14):5818-28. PubMed ID: 20587517
[TBL] [Abstract][Full Text] [Related]
2. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer.
Korkmaz KS; Elbi C; Korkmaz CG; Loda M; Hager GL; Saatcioglu F
J Biol Chem; 2002 Sep; 277(39):36689-96. PubMed ID: 12095985
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
4. Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer.
Korkmaz CG; Korkmaz KS; Kurys P; Elbi C; Wang L; Klokk TI; Hammarstrom C; Troen G; Svindland A; Hager GL; Saatcioglu F
Oncogene; 2005 Jul; 24(31):4934-45. PubMed ID: 15897894
[TBL] [Abstract][Full Text] [Related]
5. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
Chen X; Thakkar H; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
Oncogene; 2001 Sep; 20(42):6073-83. PubMed ID: 11593415
[TBL] [Abstract][Full Text] [Related]
6. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway.
Deeb D; Jiang H; Gao X; Al-Holou S; Danyluk AL; Dulchavsky SA; Gautam SC
J Pharmacol Exp Ther; 2007 May; 321(2):616-25. PubMed ID: 17289836
[TBL] [Abstract][Full Text] [Related]
7. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
Yoo J; Lee YJ
Mol Pharmacol; 2007 Dec; 72(6):1586-92. PubMed ID: 17848598
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis.
Peuhu E; Rivero-Müller A; Stykki H; Torvaldson E; Holmbom T; Eklund P; Unkila M; Sjöholm R; Eriksson JE
Oncogene; 2010 Feb; 29(6):898-908. PubMed ID: 19935713
[TBL] [Abstract][Full Text] [Related]
9. Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP.
Fujinami K; Uemura H; Ishiguro H; Kubota Y
Int J Mol Med; 2002 Aug; 10(2):173-6. PubMed ID: 12119554
[TBL] [Abstract][Full Text] [Related]
10. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells.
Sanlioglu AD; Karacay B; Koksal IT; Griffith TS; Sanlioglu S
Cancer Gene Ther; 2007 Dec; 14(12):976-84. PubMed ID: 17853923
[TBL] [Abstract][Full Text] [Related]
11. A role for the WWOX gene in prostate cancer.
Qin HR; Iliopoulos D; Semba S; Fabbri M; Druck T; Volinia S; Croce CM; Morrison CD; Klein RD; Huebner K
Cancer Res; 2006 Jul; 66(13):6477-81. PubMed ID: 16818616
[TBL] [Abstract][Full Text] [Related]
12. The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia.
Hirai K; Nomura T; Yamasaki M; Inoue T; Narimatsu T; Chisato Nakada PD; Yoshiyuki Tsukamoto PD; Matsuura K; Sato F; Moriyama M; Mimata H
Urol Oncol; 2014 Feb; 32(2):101-9. PubMed ID: 23403204
[TBL] [Abstract][Full Text] [Related]
13. Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
Lee TJ; Sartor O; Luftig RB; Koochekpour S
Mol Cancer; 2004 Nov; 3():31. PubMed ID: 15548330
[TBL] [Abstract][Full Text] [Related]
14. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
Cornforth AN; Davis JS; Khanifar E; Nastiuk KL; Krolewski JJ
Oncogene; 2008 Jul; 27(32):4422-33. PubMed ID: 18391984
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
16. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
Tong X; Li H
Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitously expressed hematological and neurological expressed 1 downregulates Akt-mediated GSK3β signaling, and its knockdown results in deregulated G2/M transition in prostate cells.
Varisli L; Gonen-Korkmaz C; Debelec-Butuner B; Erbaykent-Tepedelen B; Muhammed HS; Bogurcu N; Saatcioglu F; Korkmaz KS
DNA Cell Biol; 2011 Jun; 30(6):419-29. PubMed ID: 21323578
[TBL] [Abstract][Full Text] [Related]
18. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
[TBL] [Abstract][Full Text] [Related]
19. Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-κB transactivation in LNCaP cells.
Dasari C; Yaghnam DP; Walther R; Ummanni R
Tumour Biol; 2017 May; 39(5):1010428317698382. PubMed ID: 28466782
[TBL] [Abstract][Full Text] [Related]
20. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.
Ni J; Wen X; Yao J; Chang HC; Yin Y; Zhang M; Xie S; Chen M; Simons B; Chang P; di Sant'Agnese A; Messing EM; Yeh S
Cancer Res; 2005 Nov; 65(21):9807-16. PubMed ID: 16267002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
